Risk adjusted net present value: What is the current valuation of IN8bio’s INB-100?

Brought to you by GlobalData

Share

INB-100 is a gene-modified cell therapy commercialized by IN8bio, with a leading Phase I program in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of INB-100’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Net Present Value Model: IN8bio Inc's INB-100

Buy the Model

Data Insights

The gold standard of business intelligence.

Find out more

The revenue for INB-100 is expected to reach an annual total of $16 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

INB-100 Overview

INB-100 is under development for the treatment of leukemia like acute and chronic myelocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome and lymphoma. The therapeutic candidate is administered through parenteral route. The therapeutic candidate is developed based on drug resistant immunotherapy (DRI) platform technology and consists of genetically modified gamma delta T cells administered along with chemotherapy.

IN8bio Overview

IN8bio is a clinical-stage biopharmaceutical company that focused on discovery, and development of gamma-delta T cell product candidates for solid and liquid tumors. The company is headquartered in New York City, New York, the US.
The operating loss of the company was US$28.5 million in FY2022, compared to an operating loss of US$14.7 million in FY2021. The net loss of the company was US$28.5 million in FY2022, compared to a net loss of US$14.7 million in FY2021.

For a complete picture of INB-100’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.

More Relevant

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close